Spots Global Cancer Trial Database for Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors

Official Title: A Phase I Study And Pharmacokinetics Of Adenosine 5'- Triphosphate (ATP) When Administered By Intravenous Infusion On A Multiple Weekly Dose Schedule To Patients With Advanced Malignancies (Solid Tumors)

Study ID: NCT00014248

Conditions

Cachexia

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

adenosine triphosphate

quality-of-life assessment

Study Description

Brief Summary: RATIONALE: Adenosine triphosphate may decrease weight loss and improve muscle strength in patients with advanced solid tumors. PURPOSE: Phase I trial to study the effectiveness of adenosine triphosphate in controlling loss of weight and loss of muscle mass in patients who have advanced solid tumors.

Detailed Description: OBJECTIVES: * Determine the individualized maximum tolerated dose of adenosine triphosphate in patients with advanced solid tumors. * Determine the safety of this regimen in these patients. * Determine the pharmacokinetics of this regimen in these patients. * Determine the effect of this regimen on quality of life of these patients. * Determine the influence of this regimen on cancer cachexia in terms of weight change, percentage of body fat, voluntary muscle strength, and plasma markers in these patients. * Determine the effect of this regimen on tumor burden in these patients. OUTLINE: This is a dose-escalation study. Patients receive adenosine triphosphate (ATP) IV over 8 hours on day 0. Treatment repeats weekly for a total of 8 courses in the absence of disease progression or unacceptable toxicity. Each patient receives escalating doses of ATP until the individual maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which the patient experiences at least grade 3 (at least grade 2 cardiac ischemia or arrhythmia) toxicity. Weight is measured at baseline and at weeks 1-8, 10, and 13. Percentage of body fat and skeletal muscle strength is measured at baseline and at weeks 2, 4, 8, 10, and 13. Quality of life is assessed at baseline and at weeks 2, 4, 8, 10, and 13. Patients are followed at weeks 10 and 13. PROJECTED ACCRUAL: A maximum of 13-24 patients will be accrued for this study.